Plasma Neurofilament Heavy Chain Levels Correlate to Markers of Late Stage Disease Progression and Treatment Response in SOD1G93A Mice that Model ALS
Open Access
- 16 July 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (7) , e40998
Abstract
Amyotrophic lateral sclerosis (ALS) is an incurable neurodegenerative disorder characterised by progressive degeneration of motor neurons leading to death, typically within 3–5 years of symptom onset. The diagnosis of ALS is largely reliant on clinical assessment and electrophysiological findings. Neither specific investigative tools nor reliable biomarkers are currently available to enable an early diagnosis or monitoring of disease progression, hindering the design of treatment trials. In this study, using the well-established SOD1G93A mouse model of ALS and a new in-house ELISA method, we have validated that plasma neurofilament heavy chain protein (NfH) levels correlate with both functional markers of late stage disease progression and treatment response. We detected a significant increase in plasma levels of phosphorylated NfH during disease progression in SOD1G93A mice from 105 days onwards. Moreover, increased plasma NfH levels correlated with the decline in muscle force, motor unit survival and, more significantly, with the loss of spinal motor neurons in SOD1 mice during this critical period of decline. Importantly, mice treated with the disease modifying compound arimoclomol had lower plasma NfH levels, suggesting plasma NfH levels could be validated as an outcome measure for treatment trials. These results show that plasma NfH levels closely reflect later stages of disease progression and therapeutic response in the SOD1G93A mouse model of ALS and may potentially be a valuable biomarker of later disease progression in ALS.Keywords
This publication has 51 references indexed in Scilit:
- Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALSAmyotrophic Lateral Sclerosis, 2012
- Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALSJournal of Neurochemistry, 2011
- Evidence for acute neurotoxicity after chemotherapyAnnals of Neurology, 2010
- The Application of Biomarkers in Clinical Trials for Motor Neuron DiseaseBiomarkers in Medicine, 2010
- Arimoclomol: a potential therapy under development for ALSExpert Opinion on Investigational Drugs, 2009
- Prognostic factors in ALS: A critical reviewAmyotrophic Lateral Sclerosis, 2009
- CSF neurofilament proteins in the differential diagnosis of dementiaJournal of Neurology, Neurosurgery & Psychiatry, 2007
- Bimoclomol, a heat shock protein co-inducer, acts by the prolonged activation of heat shock factor-1Biochemical and Biophysical Research Communications, 2003
- Progressive neuronopathy in transgenic mice expressing the human neurofilament heavy gene: A mouse model of amyotrophic lateral sclerosisCell, 1993
- Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosisNature, 1993